Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA)

X
Trial Profile

A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orilanolimab (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Adverse reactions
  • Acronyms WAIHA
  • Sponsors Alexion AstraZeneca Rare Disease; Syntimmune
  • Most Recent Events

    • 19 Sep 2019 Status changed from recruiting to discontinued.
    • 17 May 2018 According to a Syntimmune media release, interim data from this trial is expected in the second half of 2018.
    • 01 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top